BNTX Relative Valuation
BNTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BNTX is overvalued; if below, it's undervalued.
Historical Valuation
Biontech SE (BNTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.02. The fair price of Biontech SE (BNTX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：96.73
Fair
-17.53
PE
1Y
3Y
5Y
Trailing
Forward
-6.50
EV/EBITDA
Biontech SE. (BNTX) has a current EV/EBITDA of -6.50. The 5-year average EV/EBITDA is 2.78. The thresholds are as follows: Strongly Undervalued below -17.00, Undervalued between -17.00 and -7.11, Fairly Valued between 12.66 and -7.11, Overvalued between 12.66 and 22.55, and Strongly Overvalued above 22.55. The current Forward EV/EBITDA of -6.50 falls within the Historic Trend Line -Fairly Valued range.
-4.05
EV/EBIT
Biontech SE. (BNTX) has a current EV/EBIT of -4.05. The 5-year average EV/EBIT is 0.39. The thresholds are as follows: Strongly Undervalued below -27.92, Undervalued between -27.92 and -13.76, Fairly Valued between 14.55 and -13.76, Overvalued between 14.55 and 28.71, and Strongly Overvalued above 28.71. The current Forward EV/EBIT of -4.05 falls within the Historic Trend Line -Fairly Valued range.
9.18
PS
Biontech SE. (BNTX) has a current PS of 9.18. The 5-year average PS is 5.95. The thresholds are as follows: Strongly Undervalued below 0.28, Undervalued between 0.28 and 3.11, Fairly Valued between 8.78 and 3.11, Overvalued between 8.78 and 11.62, and Strongly Overvalued above 11.62. The current Forward PS of 9.18 falls within the Overvalued range.
-38.39
P/OCF
Biontech SE. (BNTX) has a current P/OCF of -38.39. The 5-year average P/OCF is 1.79. The thresholds are as follows: Strongly Undervalued below -102.52, Undervalued between -102.52 and -50.37, Fairly Valued between 53.94 and -50.37, Overvalued between 53.94 and 106.10, and Strongly Overvalued above 106.10. The current Forward P/OCF of -38.39 falls within the Historic Trend Line -Fairly Valued range.
-27.65
P/FCF
Biontech SE. (BNTX) has a current P/FCF of -27.65. The 5-year average P/FCF is -9.96. The thresholds are as follows: Strongly Undervalued below -122.76, Undervalued between -122.76 and -66.36, Fairly Valued between 46.45 and -66.36, Overvalued between 46.45 and 102.85, and Strongly Overvalued above 102.85. The current Forward P/FCF of -27.65 falls within the Historic Trend Line -Fairly Valued range.
Biontech SE (BNTX) has a current Price-to-Book (P/B) ratio of 1.08. Compared to its 3-year average P/B ratio of 1.22 , the current P/B ratio is approximately -11.59% higher. Relative to its 5-year average P/B ratio of 3.95, the current P/B ratio is about -72.69% higher. Biontech SE (BNTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 17.73%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 13.95% , the current FCF yield is about -100.00% lower.
1.07
P/B
Median3y
1.22
Median5y
3.95
-2.48
FCF Yield
Median3y
17.73
Median5y
13.95
Competitors Valuation Multiple
The average P/S ratio for BNTX's competitors is , providing a benchmark for relative valuation. Biontech SE Corp (BNTX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 22.02%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BNTX decreased by 15.75% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -19.86 to -34.58.
The secondary factor is the Revenue Growth, contributed 22.02%to the performance.
Overall, the performance of BNTX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Biontech SE (BNTX) currently overvalued or undervalued?
What is Biontech SE (BNTX) fair value?
How does BNTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Biontech SE (BNTX) as of Dec 05 2025?
What is the current FCF Yield for Biontech SE (BNTX) as of Dec 05 2025?
What is the current Forward P/E ratio for Biontech SE (BNTX) as of Dec 05 2025?